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ABSTRACT 
Objective: Development and validation of a sensitive, indirect spectrophotometric kinetic method, based on oxidation-reduction reaction, using 
potassium permanganate, for the quantitative assay of pitavastatin calcium, a cardiovascular drug used for the treatment of hyperlipidemia. 
Methods: The developed spectrophotometric kinetic method is based on the ability of potassium permanganate 
Results: During the course of the reaction, the absorbance values, at 525 nm, related to KMnO
to oxidize Pitavastatin, where, the 
drug solution is treated with a fixed concentration of permanganate in acidic medium, and after a specified time, the unreacted permanganate is 
measured at 525 nm. All variables affecting the color development have been investigated and the conditions were optimized. Different kinetic 
methods, including initial rate, rate constant, fixed time and fixed concentration, were applied for the determination Pitavastatin. 
4,
Conclusion: The developed indirect spectrophotometric kinetic method, using the fixed time method, was used for the determination of 
Pitavastatin in pharmaceutical tablets. This method was simple, accurate and easy to apply for routine assay and in quality control laboratories. 
 decreased linearly with increasing the 
concentration of the drug. The reaction rate obeyed was found to be pseudo-first-order and the kinetic method used was the fixed-time method. The 
assay of PITA in the concentration range of 16-80 μg/ml, using the fixed time method was successfully determined with a correlation coefficient 
value of 0.9999. The applicability of the developed method was also demonstrated by the determination of pitavastatin in its pure form and in its 
pharmaceutical formulation, where, the effect of excipients has also been studied and found to have no effect.  
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INTRODUCTION 
The kinetic spectrophotometric method is an analytical method in which 
the rate of a reaction is measured and utilized to determine the 
concentration of drugs [1]. The application of kinetic methods of 
chemical analysis has gained increasing importance because of their high 
selectivity and sensitivity. In order to determine the amount of substance 
being analyzed in solution, it is necessary to measure the rate of decrease 
of increase of substance concentration. By applying the isolation method, 
the concentration of one of the substances (indicator substance) changes 
in the course of the reaction, and the concentration of the remaining 
substances either do not change or its change is negligible [2]. Various 
kinetic methods have been applied for the determination of many 
pharmaceutical formulations [3–7]. Potassium permanganate, a strong 
oxidizing agent, has been used in an oxidimetric analytical method for 
the determination of many compounds [8–13]. 
Pitavastatin Calcium (PIT), chemically known as (3R,5S,6E)-7-[2-
cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-
enoic acid (fig. 1), is a coenzyme A (HMG-CoA) reductase inhibitors 
(statins) that inhibits the synthesis of mevalonate, a rate-limiting 
step in cholesterol level. Competitive inhibition of HMG-CoA 
reductase by the statins decreases hepatocyte cholesterol synthesis, 
which results in increase extraction of LDL-C from the blood and 
decreases circulating LDL-C concentrations [14]. 
 
 
Fig. 1: Pitavastatin calcium 
PIT has been determined in its pharmaceutical dosage form by 
simple spectrophotometric analysis [15–18], titrimetric analysis 
[19] and liquid chromatographic analysis [20–22]. Degradation 
pathway for PIT has been developed using LC/MS method [23], or 
UPLC method [24], also photostability of PIT has been studied [25], 
In many biological fluids, PIT has been assayed by LC/MS in human 
plasma [26], urine [27]. 
Screening the literature, no kinetic method has been reported for the 
determination of PITA in pharmaceutical preparations. In the present 
work, a simple and reliable kinetically based spectrophotometric 
method is proposed for the determination of PITA in its 
pharmaceutical dosage form Livazo®
MATERIALS AND METHODS 
. The proposed method depends 
on the oxidation of the drug with potassium permanganate, where the 
A value of the excess unused permanganate is measured at 525 nm. 
The applied kinetic methods were validated according to ICH 
guidelines [28]. The results obtained were compared with those 
obtained by the RP-HPLC method [29], using the t-test and F-test [30].  
Apparatus 
Spectrophotometer 
The spectrophotometric measurements were carried out on a Jasco V-
530 double beam UV-Vis Spectrophotometer connected to a computer 
loaded with Jasco UVPC software and an HP Deskjet 5652 printer. The 
absorption spectra were measured using 1 cm quartz cells. The 
absorption spectra were recorded on the same spectrophotometer, 
with 1 cm quartz cells and supported with Jasco Spectra Manager 
software for GULLIVER Ver. 1.53, and the same printer. 
Chemicals 
PIT supplied by Algorithm-Lebanon was used as a working standard. 
An acetic acid solution obtained from SIGMA-ALDRICH was used as 
solvents for the preparation of the standard solutions. KMnO4 was 
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supplied by Fluka. The pharmaceutical preparation Livazo® was 
obtained from Algorithm-Lebanon. 
Preparation of standard solutions 
Standard stock solutions 
PIT standard stock solution (0.16 mg/ml) was prepared by 
accurately transferring 16 mg into the 100-ml volumetric flask using 
3:2, v/v acetic acid as solvent. 
KMnO4 standard solution (0.01 mole/l) was prepared by accurately 
transferring 158 mg into a 100-ml volumetric flask. The powdered 
was dissolved and diluted to the mark with distilled water. 
Calibration graph 
Accurate volumes of PIT standard stock solution were transferred into 
five separate 10-ml volumetric flasks. To each flask, 0.5 ml KMnO4 
Accurately ten tablets of Livazo 4 mg 
were added, the flasks were diluted to the mark with water to obtain a 
calibration set in the range of 16-80 µg/ml. The prepared flasks were 
kept aside at room temperature, for 30 min. The absorbance values 
were measured at 525 nm using blank solutions prepared 
simultaneously. The corresponding regression equation, relating final 
concentration versus corresponding absorbance values was derived. 
Tablet assay 
® were separately weighed and 
powdered. Accurate weight equivalent to 16 mg PIT of the finely 
powdered tablets, were transferred into the 100-ml calibrated flask, 
50 ml 3:2, v/v acetic acid was added and the flask was shaken for 15 
min, filtered and completed to volume with 3:2, v/v acetic acid. 2-ml of 
the prepared solution were transferred into 10-ml calibrated flask, 0.5 
ml, 0.01 mol/l KMnO4
RESULTS AND DISCUSSION 
 was added and the resulting solution was mixed 
and diluted to volume with water. The prepared tablet solution 
containing 32 μg/ml PIT was put aside for 30 min to allow enough 
time for the oxidation reaction to occur and the absorbance value was 
measured at 525 nm against a blank solution prepared similarly. 
The absorption spectrum of aqueous potassium permanganate 
solution in acidic medium exhibited an absorption band at 525 nm. 
The addition of the studied drug, PIT, to this solution produces a 
decrease in the intensity of this absorption band (fig. 2). This 
decrease in the absorption intensity is due to the oxidation of the 
drug by potassium permanganate in acidic medium, where 
potassium permanganate is consumed by the drug and is 
transformed into colorless manganese ions. Since the intensity of 
permanganate pink color decreases with time; therefore a kinetically 
based method was developed for the determination of PIT in its 
pharmaceutical formulation.  
Conditions optimization 
The various experimental factors affecting the development and 
stability of the reaction product were studied and optimized. Such 
factors that were changed individually, include the concentration of 
the reagents (KMnO4 and acetic acid), temperature and time. 
Effect of KMnO4 
Potassium permanganate oxidizes PIT in the presence of acetic acid, 
where it is reduced into colorless manganese ions.
concentration 
 Preliminary 
experiments were performed to determine the optimal KMnO4 
concentration, it was found that the use of 5x10-4
 
 mol/l gave 
optimum absorbance values at 525 nm. Thus, when permanganate 
was reacted with increasing concentrations of PIT in acetic acid 
medium, there occurred a concomitant fall in the concentration of 
permanganate as is shown by the decreasing absorbance values (fig. 
2). This decrease was proportional to the concentrations of PIT in 
the calibration graphs. 
 
Fig. 2: Absorption spectrum of 5x10-4 mol/l KMnO4, 16-80 μg/mlof PIT with 5x10-4 mol/lKMnO4
 
, at room T, for 30 min 
 
Fig. 3: Effect of volume of 3:2, v/v acetic acid on the absorbance of the reaction product of 32 μg/ml of PIT with 0.5 ml, 0.01 mol/l KMnO4 
at 525 nm 
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Fig. 3: Absorbance-time curve for the reaction of PIT (16-80 μg/ml) with KMnO4
 
Effect of acetic acid concentration 
To investigate the effect of acetic acid concentration on the reaction, 
1.0-6.0 ml of 3:2, v/v acetic acid were added to a fixed concentration 
of PIT (32 μg/ml) and KMnO
 in acidic medium 
4 (5x10-4
Rate = Kˊ [C]
 mol/l). After 30 min, it was 
observed that constant absorbance readings were obtained when 
different volumes of 3:2, v/v acetic acid was used (fig. 3). Hence, 
acetic acid concentration does not have any effect on the reaction 
pathway and its volume was maintained constant in all the flasks of 
the calibration graphs. 
Effect of time 
The effect of time was also studied, where the reaction was found to 
be complete and quantitative when the mixture was allowed to 
stand for 30 min, beyond this standing time and up to 40 min, the 
absorbance values remained constant (fig. 3). 
Effect of temperature 
The effect of temperature was also studied and it was found that 
providing heat to the mixture resulted in the loss of the pink color of 
permanganate where manganese dioxide brown precipitate 
appeared. Thus, room T has been chosen as the optimal temperature 
for the assay of PIT. 
Evaluation of the kinetic methods 
The quantitative determination of PIT under the optimized 
experimental conditions outlined above would result in a pseudo-
first-order reaction with respect to PIT concentration where the rate 
will be directly proportional to drug concentration in a pseudo-first-
order rate equation as follows:  
n
Where Kˊ is the rate constant and n is the order of reaction 
………… (eq. 1) 
Eq. (1) was the basis for several experiments, which were carried 
out to obtain drug concentration. The rate constant, fixed-
concentration, and fixed time methods [2], were tried and the most 
suitable analytical method was selected taking into account the 
applicability, the sensitivity, the correlation coefficient (r), and the 
intercept.  
Taking logarithms of rates and concentrations, the above equation 
becomes:  
Log (rate) = log ∆A
∆T
 = log kˊ+n log [C]………. (eq. 2) 
Where A is the absorbance, t is the time in seconds and K is the 
pseudo-first-order rate constant.  
From the absorbance-time plot, for different PIT concentration (fig. 
3), the reaction rate may be estimated by the variable-time method, 
measured as ∆A
∆T
, where A is the absorbance and t is the time in 
seconds. Regression of log (rate) versus log [C] gave the regression 
equations:  
Log (rate) =-2.46+1.10 log C (fig. 4) 
With a correlation coefficient (r) = 0.990 and with, kˊ = 3.46 x10-3 s-1
It can be concluded that the quantitative determination of PIT under 
the optimized experimental conditions outlined above would result 
in a pseudo-first-order reaction with respect to PIT concentration 
where the rate will be directly proportional to drug concentration in 
a pseudo-first-order rate equation (fig. 4). 
 
and the order of reaction is first order (n ~1). 
 
 
Fig. 4: Log rate versus log C of PIT 
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Rate-constant method  
Graphs of Log (Absorbance) versus time, over the concentration 
range of (1.65 x10-5-8.24 x10-5
υ = ΔA/Δt =-0.00017+101.7 C, r = 0.995 for PIT, k ˊ= 101.7 min
 mole/l/) (fig. 5), were plotted and all 
appeared to be rectilinear. The obtained graphs were used to 
calculate the first-order rate constants corresponding to different 
PIT concentrations. These constants were calculated from the slopes 
multiplied by (-2.303) and are presented in table 1. 
Regression of [C] versus kˊ gave the equation:  
kˊ=-0.056+118.86 C r = 0.835 
The value of the correlation coefficient (r) indicates poor linearity, 
which is probably due to changes in the rate constant (k )́ 
Initial rate method  
The initial rate of the reaction was determined from the absorbance-
time plots (fig. 3), by measuring the slopes of the initial tangents to 
the absorbance-time curves at different concentrations of the 
investigated drugs. The values of the calculated slopes are 
summarized in table 2.  
Regression of the initial rate between two and ten minutes versus 
[C] gave the equations:  
The values of the correlation coefficients (r) indicate poor linearity, 
the high wale of the rate constant Ḱ indicates that the first step is 




Fig. 5: Values of kˊ, calculated from the slopes of log A versus 
time graphs multiplied by (-2.303), four different 
concentrations of PIT 
 
Table 1: These constants were calculated from the slopes multiplied by (-2.303) and are presented 
Drug Kˊ(s C, [mol/l] -1) 












Table 2: Values of slopes calculated for different concentrations of PIT at room T with 0.5 ml 0.01 mol/l potassium permanganate 
Drug C, mol/l Slope, s-1 
PIT 1.647 x10 0.00579 -5 
3.294 x10 0.00853 -5 
4.941 x10 0.01177 -5 
6.588 x10 0.01487 -5 
8.235x10 0.01760 -5 
 
Fixed concentration method 
The kinetic study of PIT was followed up at different concentration 
levels by recording the time in seconds required for the absorbance 
to reach a preselected value. This preselected value was chosen as it 
gave the widest calibration range. The reciprocals of time (1/Δt) 
were plotted versus the initial concentration of the PIT and the 
equations of calibration graphs are given in table 3. The values of the 
correlation coefficients indicate poor linearity, which is considered a 
disadvantage.
 
Table 3: Value of (1/Δt) taken at fixed absorbance*
Drug 
 for different concentrations of PIT at room T with 0.5 ml, 0.01 mol/l potassium 
permanganate 
Δt (min) 1/Δt(s-1 C, mol/l ) Regression equation Regression coefficient (r) 
PIT 
 
15.00 0.00111 1.647 x10  -5 
1/Δt = 0.000751+11.79 C 
 










*The preselected absorbance values for PIT is 0.2 
 
Fixed time method 
Reaction rates were determined for different concentrations of PIT 
at a preselected fixed-time. Calibration graphs of absorbance versus 
concentration of PIT were established at fixed times of 15, 20, 30 
and 40 min in the concentration range of 1.647 x10-5-8.235x10-5
 
 
mol/l (16-80 μg/ml). The calculated regression equations are 
assembled at table 4. It is clear at 15 min the value of the correlation 
coefficient is poor and that indicates that the kinetic reaction did not 
reach stability. However, at 20 min the slopes increase with time and 
the most suitable values for the correlation coefficient (r) and the 
intercept (a) were obtained for a fixed-times of 30 min (table 4). 
This was therefore chosen as the most suitable time interval for 
measurement.
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Table 4: Regression equations at different fixed times for PIT at 15, 20, 30 and 40 min in the concentration range of 1.647 x10-5-8.235x10-5
Drug 
 
mol/l (16-80 μg/ml) 
Time (min) Regression equation Correlation coefficient (r) * 
PIT 15 A= 0.0372+0.00681 C 0.9940 
20 A= 0.0682+0.00798 C 0.9997 
30 A= 0.00818+0.00818 C 0.9999 
40 A= 0.09225+0.00824 C 0.9997 
 *Regression equation calculated using concentrations in μg/ml. 
 
Method validation 
Statistical evaluation of the regression line (table 5) gave small 
values for the standard deviation of residuals (Sy/x), the standard 
deviation of the slope Sb
 
. These small values reflect the high 
reproducibility of the proposed method. The limit of detection LOD 
and quantitation LOQ were calculated using the statistical treatment 
of calibration data. These statistical data challenged for the 
robustness of the fixed-time method under the optimum reaction 
condition for carrying it in the assay of PIT. 
Table 5: Analytical parameters for the determination of PIT using the fixed-time method 
Parameters PIT 
λ 525 nm 




b (slope) 0.008175 
r (correlation coefficient) 0.9999 
S 0.00346 a 
a/S 24.54 a 














LOQ (µg/ml) 4.23 
 *
 
Pharmaceutical application  
5 points, at 16-µg/ml intervals 
Assay of PIT in its pharmaceutical formulation Liv`azo® 4 mg using 
the developed method was successfully applied without interference 
from the excipients. Excellent percent recovery and RSD 
demonstrated the applicability of the method. t-test and F-test 
values were also calculated using a standard reference method [29]. 
The student t-test and variance ratio-F-test values at 95% 
confidence level did not exceed the theoretical values [30], 
indicating no significant difference in accuracy and precision of the 
proposed kinetic spectrophotometric method and the RP-HPLC-
method [29]. 
 
Table 6: Determination of PIT in pharmaceutical preparations using the fixed-time method and RP-HPLC method 






Fixed-time method RP-HPLC method  






t** = 1.49 
F** = 3.25 
amean±SD for the five determinations, b% Relative standard deviation, c% Relative error, **
 
Theoretical values of t-and F-at P = 0.05 are 2.13 and 6.93, 
respectively. 
CONCLUSION 
The low cost of the kinetic spectrophotometric technique makes it highly 
desirable for the determination of Pitavastatin in pharmaceutical 
formulations. Although the poor selectivity of the proposed methods, yet 
it is more simple, time-saving and more economic compared with HPLC 
and other sophisticated chemometric methods. These facts encourage to 
apply such methods in drug quality control laboratories.  
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